产品详情
查看大图

  • 产品名称：CRL-2547 Panc 10.05 人胰腺腺癌细胞

  • 产品型号：CRL-2547
  • 产品厂商：其它品牌
  • 产品文档：
你添加了1件商品 查看购物车
简单介绍：
简单介绍 CRL-2547 Panc 10.05 人胰腺腺癌细胞，原代细胞|细胞系|细胞株|菌种；细胞库管理规范，提供的细胞株背景清楚，提供参考文献和**培养条件！
详情介绍：

CRL-2547 Panc 10.05 人胰腺腺癌细胞 的详细介绍
L-2547 Panc 10.05 人胰腺腺癌细胞
ATCC® Number: CRL-2547™     Price:  
Designations: Panc 10.05
Depositors:  EM Jaffee
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas 
Disease: adenocarcinoma
Cellular Products: cytokeratins 7 and 18 [50655]
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Isolation: Isolation date: 1992
Tumorigenic: Yes
Oncogene: K-ras +
Antigen Expression: MHC class I +; MHC class II -
DNA Profile (STR): Amelogenin: X 
CSF1PO: 12 
D13S317: 12 
D16S539: 9,12 
D5S818: 13 
D7S820: 8,9 
THO1: 6,9.3 
TPOX: 11 
vWA: 16
Age: *****
Gender: male
Ethnicity: White
Comments: Panc 10.05 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the head-of-the-pancreas of a male with pancreatic adenocarcinoma. 
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] 
The cells have a reported plating efficiency of 40%. [50655] 
The Panc 10.05 cell line was derived from the same patient as the PL45 cell line (ATCC CRL-2558).
Propagation: ATCC complete growth medium: RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate and supplemented with 10 Units/ml human insulin, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

      Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended 
      Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 19.2 hrs
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2558
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602

沪公网安备 31010902002433号